GlassScriptPhysician profile
Kera Ashlyn Malphus
NPI 1033732755
$3,493.73
in general payments reported to CMS, 2019-2025
14 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $399 · 2023: $990 · 2024: $685 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,326 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.12 |
| Education | $390.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $983.28 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $488.10 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $424.93 | 2022-2025 | Rayaldee |
| Daiichi Sankyo INC. | $371.30 | 2023-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $348.23 | 2021-2023 | Lupkynis |
| Amgen INC. | $260.12 | 2023-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $214.62 | 2024-2025 | Jynarque |
| Horizon Therapeutics Plc | $140.81 | 2023 | Krystexxa |
| Vifor Pharma, INC. | $106.60 | 2022-2024 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $62.38 | 2024-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.78 | 2025 | Jardiance |
| Baxter Healthcare | $25.57 | 2023 | Renal - Pd |
| Novo Nordisk INC | $17.19 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $15.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kera Malphus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.